QL-1200186

Avis client

Based on 1 Customer Validation

QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM,TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté : 99.95%
  • CAS No.: 2848664-42-4
  • Formule: C26H27N7O3
  • Masse moléculaire:485.54
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs

Voir tous les produits spécifiques à Isoform STAT

More

Voir tous les produits spécifiques à Isoform Interleukin Related

More
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00